User profiles for Emma J. Crosbie
emma j crosbieVerified email at manchester.ac.uk Cited by 10127 |
Human papillomavirus and cervical cancer
EJ Crosbie, MH Einstein, S Franceschi, HC Kitchener - The Lancet, 2013 - thelancet.com
Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus
infection is harmless and clears spontaneously but persistent infection with high-risk human …
infection is harmless and clears spontaneously but persistent infection with high-risk human …
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
…, H Putter, HC Kitchener, EJ Crosbie… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
[HTML][HTML] Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
Purpose Pathogenic variants affecting MLH1, MSH2, MSH6, and PMS2 cause Lynch syndrome
and result in different but imprecisely known cancer risks. This study aimed to provide …
and result in different but imprecisely known cancer risks. This study aimed to provide …
[HTML][HTML] Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
…, A Leary, RJ Edmondson, ME Powell, EJ Crosbie… - Modern …, 2015 - nature.com
This study aimed to investigate whether molecular analysis can be used to refine risk
assessment, direct adjuvant therapy, and identify actionable alterations in high-risk endometrial …
assessment, direct adjuvant therapy, and identify actionable alterations in high-risk endometrial …
Endometrial cancer
EJ Crosbie, SJ Kitson, JN McAlpine, A Mukhopadhyay… - The Lancet, 2022 - thelancet.com
Endometrial cancer is the most common gynaecological cancer in high income countries
and its incidence is rising globally. Although an ageing population and fewer benign …
and its incidence is rising globally. Although an ageing population and fewer benign …
Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis
Background: Body mass index (BMI) is a risk factor for endometrial cancer. We quantified
the risk and investigated whether the association differed by use of hormone replacement …
the risk and investigated whether the association differed by use of hormone replacement …
[HTML][HTML] Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
…, C Genestie, IM Jürgenliemk-Schulz, EJ Crosbie… - British journal of …, 2023 - nature.com
Background Risk-assessment of endometrial cancer (EC) is based on clinicopathological
factors and molecular subgroup. It is unclear whether adding hormone receptor expression, …
factors and molecular subgroup. It is unclear whether adding hormone receptor expression, …
[HTML][HTML] The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome
… Author links open overlay panel Emma J. Crosbie PhD 1 2 3 , Neil AJ Ryan MBChB 1 4 ,
Mark J. Arends PhD 5 , Tjalling Bosse PhD 6 , John Burn MD 7 , Joanna M. Cornes BSc 8 , …
Mark J. Arends PhD 5 , Tjalling Bosse PhD 6 , John Burn MD 7 , Joanna M. Cornes BSc 8 , …
Intraoperative interventions for preventing surgical site infection: an overview of Cochrane Reviews
…, J Cawthorne, RP George, EJ Crosbie… - Cochrane Database …, 2018 - cochranelibrary.com
Background Surgical site infection (SSI) rates vary from 1% to 5% in the month following
surgery. Due to the large number of surgical procedures conducted annually, the costs of these …
surgery. Due to the large number of surgical procedures conducted annually, the costs of these …
Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications
…, S Nicholas, AH Balen, EJ Crosbie - Human reproduction …, 2014 - academic.oup.com
BACKGROUND Metformin is an effective oral anti-hyperglycaemic drug used as first-line
medical treatment for type 2 diabetes. It improves systemic hyperglycaemia by reducing hepatic …
medical treatment for type 2 diabetes. It improves systemic hyperglycaemia by reducing hepatic …